New Data on Breastfeeding Hormone May Lead to ‘Revolutionary Path’ Against Triple Negative Breast Cancer

New Data on Breastfeeding Hormone May Lead to ‘Revolutionary Path’ Against Triple Negative Breast Cancer
Researchers have discovered that high levels of prolactin receptors in triple negative breast cancer makes the tumor much less aggressive. They suggest that breastfeeding, linked to the release of the hormone prolactin, might actually protect some women from breast cancer and be used in future treatments. The study, "Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy," recently appeared in the journal Scientific Reports. The finding could spare women from harsh treatments frequently used for this type of cancer. "We think this could be a revolutionary path to developing new treatments for breast cancer," Suhad Ali, PhD, the study’s senior author from The Research Institute of the McGill University Health Centre, said in a news release. Triple negative breast cancer, named because it lacks receptors for estrogen, progesterone, and HER2, is the most aggressive type of breast cancer and notoriously difficult to treat. "While prognosis and treatment options for breast cancer patients as a whole have improved in recent decades, this is not true for women who develop triple negative breast cancer - they still have limited options for targeted treatment strategies, often require invasive chemotherapy, and have a poor prognosis," Ali said. Despite lacking the three factors that distinguish triple negative breast cancer, the disease tends to behave differently in di
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.